Ginkgo Bioworks Holdings Inc (DNA) Stock Down -2.73%: Is It a Good Investment?

Ginkgo Bioworks Holdings Inc [DNA] stock is trading at $12.82, down -2.73%. An important factor to consider is whether the stock is rising or falling in short-term value. The DNA shares have gain 25.69% over the last week, with a monthly amount glided 27.18%, and seem to be holding up well over a long-time horizon.

From an analyst’s perspective:

Ginkgo Bioworks Holdings Inc [NYSE: DNA] stock has seen the most recent analyst activity on May 15, 2024, when BTIG Research downgraded its rating to a Sell. Previously, William Blair downgraded its rating to Underperform on May 10, 2024. On November 14, 2023, downgrade downgraded it’s rating to Mkt Perform and revised its price target to $2.50 on the stock. BTIG Research downgraded its rating to a Neutral. Goldman downgraded its rating to a Sell and reduced its price target to $1.25 on June 02, 2023. William Blair downgraded its rating to Mkt Perform for this stock on May 11, 2023. In a note dated November 29, 2022, Berenberg initiated an Buy rating and provided a target price of $6 on this stock.

Ginkgo Bioworks Holdings Inc [DNA] stock has fluctuated between $5.26 and $64.40 over the past year. Currently, Wall Street analysts expect the stock to reach $7 within the next 12 months. Ginkgo Bioworks Holdings Inc [NYSE: DNA] shares were valued at $12.82 at the most recent close of the market. An investor can expect a potential drop of -45.4% based on the average DNA price forecast.

Analyzing the DNA fundamentals

Ginkgo Bioworks Holdings Inc [NYSE:DNA] reported sales of 217.95M for the trailing twelve months, which represents a growth of 60.65%. Gross Profit Margin for this corporation currently stands at 0.64% with Operating Profit Margin at -2.71%, Pretax Profit Margin comes in at -2.99%, and Net Profit Margin reading is -2.99%. To continue investigating profitability, this company’s Return on Assets is posted at -0.44, Equity is -0.7 and Total Capital is -0.43. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.56.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 12.20 points at the first support level, and at 11.58 for the second support level. However, for the 1st resistance point, the stock is sitting at 13.84, and for the 2nd resistance point, it is at 14.86.

Ratios To Look Out For

For context, Ginkgo Bioworks Holdings Inc’s Current Ratio is 5.79. On the other hand, the Quick Ratio is 5.79, and the Cash Ratio is 5.39. Considering the valuation of this stock, the price to sales ratio is 3.38, the price to book ratio is 0.80.

Transactions by insiders

Recent insider trading involved Che Austin, Officer, that happened on Jan 24 ’25 when 99.0 shares were purchased. Officer, Che Austin completed a deal on Jan 23 ’25 to buy 99.0 shares. Meanwhile, Officer Che Austin bought 99.0 shares on Jan 22 ’25.

Related Posts